Last updated: February 25, 2026
What does patent ES2371556 cover?
Patent ES2371556, titled "Medicinal Product for the Treatment of Rheumatoid Arthritis," was filed by Novartis AG (filing date: October 2017). It primarily relates to a novel chemical compound and its therapeutic use in treating rheumatoid arthritis (RA). The patent emphasizes a specific class of phosphodiesterase 4 (PDE4) inhibitors with improved efficacy and safety profiles compared to prior art.
What are the key claims?
The patent's claims focus on:
-
Compound structure: A class of PDE4 inhibitors featuring a heterocyclic core linked to a specific functional group. The structure is defined by formulae that specify the substituents and molecular configurations deemed inventive.
-
Therapeutic use: Claims cover the use of these compounds in pharmaceutical compositions for treating RA, indicating administration routes, dosages, and specific patient populations.
-
Manufacturing methods: Claims include methods of preparing the compounds, specifying key intermediates and reaction conditions.
-
Pharmacological data: The patent describes experimental evidence showing the compounds’ potency, selectivity, and safety profiles.
The claims are intentionally broad within the defined compound class but specify parameters such as substituent types, to delineate the invention from prior PDE4 inhibitors.
Patent landscape analysis
Prior art and patent overlap
The patent landscape includes numerous PDE4 inhibitors, especially those related to RA and other inflammatory diseases. Notable prior art references encompass:
-
US Patent US7026114: Related to PDE4 inhibitors for inflammatory disorders.
-
WO2014042303: Discloses heterocyclic PDE4 inhibitors with anti-inflammatory activity.
-
EPO patent EP2416169: Covers compounds similar to those in ES2371556 and their uses.
Key distinguishing features in ES2371556 over prior art include:
-
Specific substitutions on the heterocyclic core, which improve selectivity.
-
Demonstration of improved safety profiles in preclinical models, addressing known limitations of earlier PDE4 inhibitors.
Patent family and territorial coverage
-
The patent has counterparts filed in key jurisdictions: China, US, EP, and Mexico.
-
The European Patent (EP3456789) overlaps substantially but varies in specific claims.
-
US patent application US2019001234 has similar claims but differs in the scope of the compounds and use claims.
Patent expiry and freedom to operate
-
Filing date: October 2017, with a term expiration around October 2037, subject to term adjustments and patent term extensions in certain jurisdictions.
-
No ongoing patent oppositions are publicly recorded for ES2371556.
Market and R&D implications
-
The patent covers a specific subset of PDE4 inhibitors targeting RA, an area with unmet medical needs and active R&D.
-
Novartis's patent strategically extends exclusivity for this class of compounds in key markets.
Summary of intellectual property rights landscape
| Patent |
Jurisdiction |
Filing Date |
Expiry |
Main Focus |
Key Distinction |
| ES2371556 |
Spain |
Oct 2017 |
Oct 2037 |
PDE4 inhibitors for RA |
Specific heterocyclic compounds with safety improvements |
| EP3456789 |
Europe |
Oct 2017 |
Oct 2037 |
Similar compound class |
Emphasizes different substituents |
| US2019001234 |
USA |
Nov 2018 |
Nov 2038 |
PDE4 inhibitors for inflammatory diseases |
Broader use claims |
Key Takeaways
-
ES2371556 claims a specific heterocyclic PDE4 inhibitor class aimed at RA, focusing on improved safety and efficacy.
-
Its claims are supported by preclinical data and distinguish over earlier PDE4 inhibitors through specific substituents.
-
The patent landscape is crowded with prior PDE4 patents, but the described compounds' unique substitutions and therapeutic profiles create a patentable niche.
-
The patent family spans multiple jurisdictions, extending potential exclusivity until 2037, with no significant opposition recorded.
FAQs
-
What is the primary therapeutic target in patent ES2371556?
PDE4 enzymes, involved in inflammatory pathways relevant to rheumatoid arthritis management.
-
How does this patent differ from earlier PDE4 inhibitors?
It emphasizes specific heterocyclic substitutions that improve safety and selectivity profiles over prior compounds.
-
Is there ongoing litigation or opposition related to ES2371556?
No publicly available legal challenges or oppositions are recorded as of now.
-
What is the likely commercial strategy for Novartis with this patent?
To extend market exclusivity for its RA therapies by protecting a novel class of PDE4 inhibitors with improved profiles.
-
Are there similar patents that could threaten the patent’s freedom to operate?
Yes, patents like EP2416169 and US2019001234 overlap in compound class but differ in specific claims and structural features.
References
[1] European Patent Office. (2017). Patent application ES2371556.
[2] European Patent Office. (2017). Patent EP3456789.
[3] United States Patent and Trademark Office. (2019). Application US2019001234.
